Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced unaudited fourth quarter and full-year 2012 revenues and provided business updates, including the expected timing of data readouts for two ongoing Phase 3 clinical trials of CXA-201 (ceftolozane/tazobactam).
Cubist continued to deliver double-digit total revenue growth in the fourth quarter. Fourth quarter and year-end 2012 unaudited revenue results include:
- Total net revenues for Q4 2012 of $245.9 million were up 16% compared to Q4 of 2011. Full-year 2012 total net revenues were $926.4 million, up 23% compared to $754.0 million in 2011.
- U.S. CUBICIN® (daptomycin for injection) net product revenues in Q4 2012 increased 14% to $216.0 million from $190.1 million in Q4 2011. Full-year 2012 total U.S. CUBICIN net product revenues were $809.2 million, up 16% compared to $698.8 million in 2011.
- International CUBICIN revenues for Q4 2012 increased 34% to $14.5 million from $10.8 million in Q4 2011. Full-year 2012 total international CUBICIN revenues were $50.5 million, up 38% compared to $36.7 million in 2011.
- ENTEREG® (alvimopan) net product revenues were $10.9 million in the fourth quarter of 2012. Full-year 2012 total ENTEREG net product revenues were $40.2 million.
- Service revenues for DIFICID® (fidaxomicin) in the fourth quarter of 2012 were $3.7 million. Full-year 2012 total services revenues for DIFICID were $23.2 million.
Cubist also provided an update regarding ceftolozane/tazobactam, currently being studied in pivotal Phase 3 trials as a first-line intravenous therapy for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) caused by Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa. Top-line data readouts from these two clinical trials are expected in the second-half of 2013. This timing incorporates a reduction of patient enrollment requirements and reflects the Company’s recent consultation with the Food and Drug Administration (FDA), following the release by the FDA in late September of new draft guidance for cIAI registration trials. Cubist anticipates filing a New Drug Application (NDA) for ceftolozane/tazobactam in cUTI and cIAI approximately six months after announcing top-line results from the Phase 3 trials. As recently announced, the FDA granted ceftolozane/tazobactam a Qualified Infectious Disease Products (QIDP) designation, qualifying it for priority review and fast-track status at the FDA. If ultimately approved by the FDA, it would also receive a five-year extension of Hatch-Waxman exclusivity.
“We had another strong year in 2012, driven in large measure by the continued growth of CUBICIN. As we enter 2013, and anticipate Phase 3 data for ceftolozane/tazobactam, we expect to begin the next significant chapter of Cubist’s growth story,” said Michael Bonney, Chief Executive Officer. “We continue to demonstrate the value of our differentiated focus on the acute care market. We are advancing three Phase 3 product candidates, including ceftolozane/tazobactam, which we believe has blockbuster potential based on its unique attributes and the significant need for new antibiotics to treat infections caused by multi-drug resistant Gram-negative pathogens. As we move forward in 2013, we will continue to focus on driving shareholder value by executing against our Building Blocks of Growth five-year goals.”Mr. Bonney will present to investors at the 31st Annual J.P. Morgan Healthcare Conference at 2:00 p.m. ET / 11:00 a.m. PT on January 10th, 2013. The presentation will be available via webcast at www.cubist.com. During his presentation, Mr. Bonney will discuss the Company’s unaudited 2012 revenue results, the company’s business strategy and market opportunities, and will highlight additional recent pipeline developments, including:
- The updated timing for anticipated top-line data from ceftolozane/tazobactam’s Phase 3 studies in cUTI and cIAI;
- CB-315’s recent QIDP designation, and Phase 3 trials now underway in Clostridium difficile-associated diarrhea (CDAD); and
- The bevenopran (CB-5945) Phase 3 program to develop a potential therapy for patients with opioid-induced constipation (OIC) which began in October 2012 with the initiation of a large, well-controlled, long-term safety trial. Three Phase 3 efficacy trials are planned to begin in the first half of 2013.
|******************Q4 2012 CONFERENCE CALL & WEBCAST INFORMATION******************Cubist will host a conference call and live audio webcast to discuss both its fourth quarter andfull-year 2012 financial results, business activities and financial outlook.WHEN: Wednesday, January 23, 2013 at 5:00 p.m. ETLIVE DOMESTIC & CANADA CALL-IN: (855) 319-7654LIVE INTERNATIONAL CALL-IN: (484) 756-4327Attendee Passcode: 8398635724-HOUR REPLAY DOMESTIC & CANADA: (855) 859-205624-HOUR REPLAY INTERNATIONAL: (404) 537-3406REPLAY PASSCODE:Conference ID: 83986357CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.comReplay will be available for 90 days via the Internet at www.cubist.com**********************************************************************|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV